Avicena Receives Additional U.S. Patent Claim Covering Use of Creatine or Creatine Compounds for Skin Preservation
Claim Accepted for Treatment Method for Uneven Skin Pigmentation
Palo Alto, CA, March 7, 2007 — Avicena® Group, Inc. (OTCBB:AVGO), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,186,754, entitled, "Use of Creatine or Creatine Compounds for Skin Preservation," on March 6, 2007. The newly issued patent contains claims which cover methods and compositions for treating uneven skin pigmentation using a topical application of creatine and carnitine. This patent enhances the Company's skin care patent portfolio, which also contains U.S. Patent No. 6,242,491, with claims directed to methods for treating skin damage resulting from sun radiation, stress, fatigue or free radicals by administering creatine.
"We are extremely pleased to have received this additional patent claim to broaden our IP position in dermaceuticals," stated Dr. Belinda Tsao-Nivaggioli, Avicena's Chief Executive Officer.
Dr. Tsao-Nivaggioli continued, "The discovery that a composition of creatine and carnitine is an effective treatment for uneven skin pigmentation provides a new approach to a very common dermatological problem."
Avicena® Group, Inc. (OTCBB: AVGO) is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). Near term, Avicena intends to initiate both a Phase III trial in Huntington's disease, and a Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary ingredients to skin care manufacturers.
This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" in the company's prospectus for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
The Ruth Group (on behalf of The Avicena Group)
Sara Ephraim / John Quirk (investors)
(646) 536-7002 / 7029
Janine McCargo / Jason Rando (media)
(646) 536-7033 / 7025